ImmuPharma plc (LON:IMM – Get Free Report) fell 11.6% during trading on Thursday . The stock traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.57 ($0.03). 6,519,809 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 11,538,609 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Trading Down 4.8 %
The firm has a market cap of £10.78 million, a P/E ratio of -4.39 and a beta of 1.53. The business’s 50-day moving average is GBX 3.92 and its two-hundred day moving average is GBX 2.48.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Investing In Automotive Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- Best Stocks Under $5.00
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Compound Interest and Why It Matters When Investing
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
